posted on 5 November 2009 4:28PM EST
Using an RNA-powered nanomotor, University of Cincinnati (UC) biomedical engineering scientists successfully developed an artificial pore able to transmit nanoscale material through a membrane.
In a study led by Dr. Peixuan Guo, members of the UC team inserted the modified core of a nanomotor into a lipid membrane. The resulting channel enabled them to move both single- and double-stranded DNA through the membrane.
During this week's podcast Dr. Guo talks about the creation of the RNA nanomotor and provides additional ...more.
posted on 4 November 2009 6:29PM EST
Drug delivery seems to be a major theme here this year. I hope Light Sciences Oncology CEO Llew Keltner will forgive my stretching the concept to include the technology his company has developed which is promising to make light-activated therapy for cancer a clinical reality. The traditional approach to light-activated therapy uses a laser to deliver the light, which is not really practical in the clinic. The LSO product, Aptocine ™ is a combination of an LED array delivered to a tumor via biopsy and a non-toxic water soluble photosensitive compound, talaporfin sodium. Phase III results in ...more.
posted on 4 November 2009 7:11AM EST
BIO-Europe 2009 Day 2
An interesting deal announced here is between Malaysian drug delivery company SIOGEN Biotech and Grampian Bioconsultants Ltd, a recent spinout from Aberdeen University with a focus on immunotherapy and cancer. SIOGEN was voted the most innovative biotech startup in the Asia Pacific region for 2009. The company’s Designer Siosomes ® are liposome-like nanoparticles based upon silicon. Grampian will couple antibodies onto the surface of the Siosomes for more accurate delivery into tissues like lung and heart. SIOGEN Exec Chairman Zoser Salama thinks Siosomes ...more.
posted on 3 November 2009 7:47AM EST
BIO-Europe 2009 Day 1
Greetings from snowy Vienna, where I am representing GEN at BIO-Europe 2009. There’s lots to discover – as there are over 1,400 companies here (many of them old friends of GEN, but probably more that are completely unknown to me!). My first discovery is Mercordia, a Swedish company developing a diagnostic test for oxidised LDL. Sounds like this could be a good marker to add to a lipid panel – the clinical rationale seems strong. Next, I’m told (by Belgian consultant Thérèse Delatte) that Pharmadiagnostics is a company to watch. Why? Because ...more.
posted on 30 October 2009 6:10PM EST
Gail Dutton
I’ve debated about this post for a long time now, and not wanting to believe that what I am seeing could possibly be happening. Surely some critical piece of information was missing that could prove me wrong. Well, it probably is missing, but I’ve come to the conclusion that entrepreneurs in the U.S. should be afraid, very afraid. And, lest the point be overlooked, biotech companies ARE entrepreneurial.
Point 1. The U.S. government took over two of our three car companies, tossing out contract law and shareholder rights. Last autumn, the government bailed ...more.
pages: 1 2 3 4 5 6 7 8 9 10 11 >>
NOTICE: As such, the comments on this blog were, are, and will always be solely the opinions of the individuals leaving them. In no way does Genetic Engineering & Biotechnology News, GEN Publishing, Inc., or Mary Ann Liebert ,Inc. endorse, condone, agree with, sponsor, etc. these comments.
ADVERTISEMENT
INTERVIEW:
NANOTECHNOLOGISTS CREATE ARTIFICIAL PORE - Interview with Peixuan Guo, Ph.D., Director of the NIH Nanomedicine Development Center at the University of Cincinnati, Endowed Chair, and Professor of Biomedical Engineering
...MORE
NewsArticles Blogs| Most Viewed | Most Emailed | Top Searches |
|---|---|---|
| BIO-Europe 2009 Day 3 | ||
| New Recommendations for Gene Patents - Thank Goodness! | ||
ADVERTISEMENT
Subscribe to RSS
HOME
Hot Topics
All Topics
Archived
Post a Topic
RSS
Listen
Save
Comment